276 related articles for article (PubMed ID: 30591488)
21. Anaplastic Lymphoma Kinase Mutation (
Carneiro BA; Pamarthy S; Shah AN; Sagar V; Unno K; Han H; Yang XJ; Costa RB; Nagy RJ; Lanman RB; Kuzel TM; Ross JS; Gay L; Elvin JA; Ali SM; Cristofanilli M; Chae YK; Giles FJ; Abdulkadir SA
Clin Cancer Res; 2018 Jun; 24(12):2732-2739. PubMed ID: 29559559
[No Abstract] [Full Text] [Related]
22. Large Cell Neuroendocrine Carcinoma of the Lung: Clinico-Pathologic Features, Treatment, and Outcomes.
Naidoo J; Santos-Zabala ML; Iyriboz T; Woo KM; Sima CS; Fiore JJ; Kris MG; Riely GJ; Lito P; Iqbal A; Veach S; Smith-Marrone S; Sarkaria IS; Krug LM; Rudin CM; Travis WD; Rekhtman N; Pietanza MC
Clin Lung Cancer; 2016 Sep; 17(5):e121-e129. PubMed ID: 26898325
[TBL] [Abstract][Full Text] [Related]
23. P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung Cancer.
Katayama R; Sakashita T; Yanagitani N; Ninomiya H; Horiike A; Friboulet L; Gainor JF; Motoi N; Dobashi A; Sakata S; Tambo Y; Kitazono S; Sato S; Koike S; John Iafrate A; Mino-Kenudson M; Ishikawa Y; Shaw AT; Engelman JA; Takeuchi K; Nishio M; Fujita N
EBioMedicine; 2016 Jan; 3():54-66. PubMed ID: 26870817
[TBL] [Abstract][Full Text] [Related]
24. Distinct clinicopathologic features, genomic characteristics and survival of central and peripheral pulmonary large cell neuroendocrine carcinoma: From different origin cells?
Zhou F; Hou L; Ding T; Song Q; Chen X; Su C; Li W; Gao G; Ren S; Wu F; Fan J; Wu C; Zhang J; Zhou C
Lung Cancer; 2018 Feb; 116():30-37. PubMed ID: 29413048
[TBL] [Abstract][Full Text] [Related]
25. [Histologic subtyping of poorly-differentiated solid lung cancer with molecular testing for epidermal growth factor receptor mutation and ALK gene rearrangement: an analyses of 167 cases].
Fang F; Wang YX; Hu ST; Yang L; Di J; Liu DG; Lyu N
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):432-437. PubMed ID: 29886587
[No Abstract] [Full Text] [Related]
26. Identification of anaplastic lymphoma kinase fusions in clear cell renal cell carcinoma.
Chen W; Li W; Bai B; Wei H
Oncol Rep; 2020 Mar; 43(3):817-826. PubMed ID: 32020234
[TBL] [Abstract][Full Text] [Related]
27. Detection of novel and potentially actionable anaplastic lymphoma kinase (ALK) rearrangement in colorectal adenocarcinoma by immunohistochemistry screening.
Lee J; Kim HC; Hong JY; Wang K; Kim SY; Jang J; Kim ST; Park JO; Lim HY; Kang WK; Park YS; Lee J; Lee WY; Park YA; Huh JW; Yun SH; Do IG; Kim SH; Balasubramanian S; Stephens PJ; Ross JS; Li GG; Hornby Z; Ali SM; Miller VA; Kim KM; Ou SH
Oncotarget; 2015 Sep; 6(27):24320-32. PubMed ID: 26172300
[TBL] [Abstract][Full Text] [Related]
28. Integrin β3 Inhibition Enhances the Antitumor Activity of ALK Inhibitor in
Noh KW; Sohn I; Song JY; Shin HT; Kim YJ; Jung K; Sung M; Kim M; An S; Han J; Lee SH; Lee MS; Choi YL
Clin Cancer Res; 2018 Sep; 24(17):4162-4174. PubMed ID: 29776956
[No Abstract] [Full Text] [Related]
29. ALK-rearranged pulmonary adenocarcinoma in Thai Patients: From diagnosis to treatment efficacy.
Incharoen P; Reungwetwattana T; Saowapa S; Kamprerasart K; Pangpunyakulchai D; Arsa L; Jinawath A
World J Surg Oncol; 2016 May; 14():139. PubMed ID: 27142166
[TBL] [Abstract][Full Text] [Related]
30. DLL3 expression in large cell neuroendocrine carcinoma (LCNEC) and association with molecular subtypes and neuroendocrine profile.
Hermans BCM; Derks JL; Thunnissen E; van Suylen RJ; den Bakker MA; Groen HJM; Smit EF; Damhuis RA; van den Broek EC; ; Ruland A; Speel EJM; Dingemans AMC
Lung Cancer; 2019 Dec; 138():102-108. PubMed ID: 31678831
[TBL] [Abstract][Full Text] [Related]
31. The use of alectinib in the first-line treatment of anaplastic lymphoma kinase-positive non-small-cell lung cancer.
Gadgeel SM
Future Oncol; 2018 Aug; 14(18):1875-1882. PubMed ID: 29536761
[TBL] [Abstract][Full Text] [Related]
32. A case report: Pharmacology and resistance patterns of three generations of ALK inhibitors in metastatic inflammatory myofibroblastic sarcoma.
Parker BM; Parker JV; Lymperopoulos A; Konda V
J Oncol Pharm Pract; 2019 Jul; 25(5):1226-1230. PubMed ID: 29925295
[TBL] [Abstract][Full Text] [Related]
33. Inflammatory Myofibroblastic Tumor Driven by Novel
Rao N; Iwenofu H; Tang B; Woyach J; Liebner DA
J Natl Compr Canc Netw; 2018 Feb; 16(2):115-121. PubMed ID: 29439172
[TBL] [Abstract][Full Text] [Related]
34. Sequential Use of Anaplastic Lymphoma Kinase Inhibitors in Japanese Patients With ALK-Rearranged Non-Small-Cell Lung Cancer: A Retrospective Analysis.
Asao T; Fujiwara Y; Itahashi K; Kitahara S; Goto Y; Horinouchi H; Kanda S; Nokihara H; Yamamoto N; Takahashi K; Ohe Y
Clin Lung Cancer; 2017 Jul; 18(4):e251-e258. PubMed ID: 28065466
[TBL] [Abstract][Full Text] [Related]
35. Detection of ALK rearrangement by immunohistochemistry in lung adenocarcinoma and the identification of a novel EML4-ALK variant.
To KF; Tong JH; Yeung KS; Lung RW; Law PP; Chau SL; Kang W; Tong CY; Chow C; Chan AW; Leung LK; Mok TS
J Thorac Oncol; 2013 Jul; 8(7):883-91. PubMed ID: 23625156
[TBL] [Abstract][Full Text] [Related]
36. Two case reports: EML4-ALK rearrangement large cell neuroendocrine carcinoma and literature review.
Chen Q; Zhang J; Wang X; Zong W; Sun L; Qin J; Yin Y
Front Oncol; 2023; 13():1227980. PubMed ID: 38023218
[TBL] [Abstract][Full Text] [Related]
37. PLEKHM2-ALK: A novel fusion in small-cell lung cancer and durable response to ALK inhibitors.
Li T; Zhang F; Wu Z; Cui L; Zhao X; Wang J; Hu Y
Lung Cancer; 2020 Jan; 139():146-150. PubMed ID: 31794921
[TBL] [Abstract][Full Text] [Related]
38. ALK-rearranged lung squamous cell carcinoma responding to alectinib: a case report and review of the literature.
Mamesaya N; Nakashima K; Naito T; Nakajima T; Endo M; Takahashi T
BMC Cancer; 2017 Jul; 17(1):471. PubMed ID: 28683775
[TBL] [Abstract][Full Text] [Related]
39. ALK rearranged renal cell carcinoma (ALK-RCC): a multi-institutional study of twelve cases with identification of novel partner genes CLIP1, KIF5B and KIAA1217.
Kuroda N; Trpkov K; Gao Y; Tretiakova M; Liu YJ; Ulamec M; Takeuchi K; Agaimy A; Przybycin C; Magi-Galluzzi C; Fushimi S; Kojima F; Sibony M; Hang JF; Pan CC; Yilmaz A; Siadat F; Sugawara E; Just PA; Ptakova N; Hes O
Mod Pathol; 2020 Dec; 33(12):2564-2579. PubMed ID: 32467651
[TBL] [Abstract][Full Text] [Related]
40. Expression and copy number gains of the RET gene in 631 early and mid stage non-small cell lung cancer cases.
Tan L; Hu Y; Tao Y; Wang B; Xiao J; Tang Z; Lu T; Tang H
Thorac Cancer; 2018 Apr; 9(4):445-451. PubMed ID: 29473341
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
